Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eltrombopag - Novartis

X
Drug Profile

Eltrombopag - Novartis

Alternative Names: 497115; Eltrombopag olamine; ETB-115; Promacta; Reboredo; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer French Innovative Leukemia Organisation; GlaxoSmithKline; Groupe Francophone des Myelodysplasies; GSK; Novartis; Technische Universitat Dresden
  • Class Antianaemics; Antineoplastics; Benzoates; Biphenyl compounds; Carboxylic acids; Hydrazines; Pyrazoles; Radioprotectives; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase III Acute radiation syndrome
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Transplant rejection
  • Phase I/II Chronic myelomonocytic leukaemia

Most Recent Events

  • 22 Sep 2023 Novartis Pharmaceuticals completes the phase II trial in Idiopathic thrombocytopenic purpura (Newly diagnosed, Combination therapy) in Germany (PO) (NCT04346654)
  • 17 May 2023 Novartis completes a phase II trial in Aplastic anaemia in China (PO) (NCT03988608)
  • 10 Dec 2022 Adverse events, efficacy and pharmacokinetics data from the phase II ESCALATE trial in Aplastic anaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top